As p53 mutations are common in human cancer, including PDAC, we have pursued therapeutic targeting of tumors with mutant p53 (Wang et al., 2006; Bassett et al., 2008; Hernández Borrero and El-Deiry, 2021). This evidence concerns the gene TP53 and cancer.